clindamycin hydrochloride

01 02 03

General content

Your present location:General content

Topical clindamycin hydrochloride 1% in acne vulgaris Khanna VN

Number of visits:976 Date:2016/1/7 7:30:55
Topical clindamycin hydrochloride 1% in acne vulgaris Khanna VN

Twenty six patients with moderately severe acne were treated for 12 weeks with topical clindamycin hydrochloride 1% (12 patients) and the vehicle (14 patients). A good or excellent reduction was seen in the non-inflammatory acne lesion count in 3 (25%) of the patients on topical clindamycin and in none of the patients who used the vehicle (control).While 9 (75%) of the patients using topical clindamycin hydrochloride showed a good to excellent response in their inflammatory acne lesion count, only 2 (14.29%) of the control group showed a similar response. The response of the non-inflammatory acne to topical clindamycin hydrochloride 1% was comparable to that of the vehicle, (p >0.05) while the response of inflammatory acne lesions to topical clindamycin hydrochloride 1% was superior to that of the vehicle (p <0.05)

clindamycin hydrochloride Materials and methods

A double-blind, randomised 12-week study was conducted to evaluate the efficacy in acne vulgaris of clindamycin hydrochloride 1 % in an hydro-alcoholic vehicle as compared to the vehicle used alone. The study population was made up of 29 patients, aged 14-23 years, with moderately severe acne vulgaris. Moderately severe acne was defined as the presence, on the face (above the jawline) of the subject, of 5-15 inflammatory lesions (IN) but no more than 5 nodulocystic lesions and / or more than 50 non-inflammatory (NI) acne lesions. None of the patients had received any anti-acne therapy within the previous 30 days and none of the female patients taken up for the trial, were taking any oral contraceptives or were pregnant.

Patients were randomly assigned to one of the two treatment schedules (a) clindamycin hydrochloride 1% in a hydro-alcoholic vehicle to be applied topically twice a day (b) the hydro­alcoholic vehicle to be applied topically twice a day (used as a control).

The efficacy of the drugs was evaluated at four weekly intervals by spot counting of the acne lesions, done by the same observer. The criteria for effectiveness of the treatment was the reduction in the number of NI and IN lesions at the end of 12 weeks. The improvement was graded as follows : (1) excellent, when there was more than 75% reduction in the lesion count, (2) good, when there was 50-75% reduction in the lesion count, (3) fair, when there was a 25-50% reduction in the lesion count , (4) poor, when there was less than 25% reduction in the lesion count, and (5) worse, when there was an increase in the lesion count.

In addition the mean reduction of the NI and IN lesions was calculated for each of the two therapeutic groups. The response was statistically evaluated using a paired t-test. A p value of < 0.05 were considered statistically significant.

clindamycin hydrochloride Results


A total of 29 (19 males and 10 femal6s) patients were taken up for the study. Twenty six ( 12 using topical clindamycin hydrochloride 1% and 14 using the vehicle) could be followed up for the stipulated 12 weeks. The clinical response of the NI and IN lesions of acne vulgaris to topical clindamycin hydrochloride 1 and to the vehicle, when used alone, is depicted in [Table - 1][Table - 2]. The response of IN acne lesions to topical clindamycin hydrochloride 1% was superior to that if the hydro-alcoholic vehicle and this difference was statistically significant (p=0.007). Though it seemed that NI acne lesions also responded to topical clindamycin hydrochloride 1%, there was statistically no significant difference in this response, when compared to the response with the vehicle (p=0.65).

Side effects were observed in 2/12 (16.67%) patients using topical clindamycin hydrochloride and in 3/14 (21.43%) patients using the vehicle. These patients developed mild burning, dryness, erythema, itching and peeling of the skin. None of these side effects were severe enough to necessitate withdrawal of therapy. None of the patients using clindamycin topically developed any gastro­intestinal side effects.

Previous post:
Pharmacokinetics of clindamycin hydrochloride in pregnant women

Next post:
Clindamycin hydrochloride in the treatment of acute pelvic inflammation of gynaecology
Welcome to our website!BACK TO HOME >>